权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Translational and Clinical Research (TACR)

转化和临床研究（TACR）

基本信息

批准号：
10627257
负责人：
THEODORE S LAWRENCE
金额：
$ 11.82万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-06-01 至 2028-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10627257
关键词：
Animal Model Area Biological Markers Bladder Breast Cancer Center Cancer Center Support Grant Cancer Control Cancer Detection Catchment Area Cells Classification Clinical Data Clinical Oncology Clinical Protocols Clinical Research Clinical Trials Clinical Trials Design Collaborations Colorectal Community Outreach Data Science Developmental Therapeutics Program Direct Costs Disease Drug Kinetics Drug Screening Early Diagnosis Enrollment Environment Equity Flow Cytometry Funding Genes Genetic Determinism Glossary Goals Grant Hematopoiesis Heterogeneity Immunity Immunologic Monitoring Immunology Industry Inflammation Institution Journals Laboratories Life Link Liver Lung Malignant Neoplasms Measures Michigan Microbe Molecular Molecular Target Monitor Multiple Myeloma Names National Clinical Trials Network Nature Pancreas Paper Patients Peer Review Physicians Population Sciences Prevention Prostate Proteomics Protocols documentation Publications Publishing Quality of Care Research Research Priority Resistance Resource Sharing Risk Reduction Schools Science Scientist Sensitivity and Specificity Signal Transduction Site Solid Neoplasm Structure System Testing Therapeutic Therapeutic Intervention Therapeutic Trials Tissue imaging Tissues Training and Education Transgenic Animals Translating Translational Research Universities Uterus cancer care cancer diagnosis cancer genetics cancer initiation cancer risk cancer therapy care delivery cellular imaging clinical translation college community engagement data management health communication improved innovation irradiation member molecular imaging molecular pathology novel strategies participant enrollment patient oriented research patient subsets personalized medicine pre-clinical predictive marker programs resistance mechanism single cell analysis translational approach tumor tumor metabolism tumor microenvironment

项目摘要

PROJECT SUMMARY/ABSTRACT (TRANSLATIONAL AND CLINICAL RESEARCH) The Translational and Clinical Research (TACR) Program catalyzes collaborations along the laboratory- translational-clinical research continuum and across solid tumor disease sites in the University of Michigan (U- M) Rogel Cancer Center (Rogel). TACR represents a crucial bridging mechanism for the Rogel, linking its laboratory and population science based-research programs that generate innovative concepts, agents, and approaches that TACR translates to solid tumor patient-oriented research. The TACR Program is comprised of 79 members from 15 different departments and four different schools and colleges. In 2022, TACR Program members had a total of $20.8M in annual direct cancer-relevant funding, of which $7.5M (36%) was from NCI; the Program had a total of $10.2M (49%) in peer-reviewed funding. In addition, TACR members had $10.6 million in grants from non-peer and industry sponsors. Members have a total of 1457 publications, of which 30.1% are intra-programmatic and 34.8% are inter-programmatic collaborations. The TACR program has three Specific Aims: 1) Develop and apply state-of-the-art molecularly targeted approaches to cancer diagnosis and treatment; 2) Develop and test new predictive biomarker and disease-monitoring strategies across tumor types; and 3) Advance concepts emanating from Rogel Cancer Center scientific programs to impactful clinical trials.

项目摘要/摘要(翻译和临床研究) 转化和临床研究(TACR)计划促进实验室之间的合作- 密歇根大学跨实体肿瘤疾病部位的翻译-临床研究连续体 M)罗杰尔癌症中心(Rogel)。TACR代表了Rogel的一个关键的桥梁机制，将其以实验室和人口科学为基础的研究计划，产生创新的概念、试剂和 TACR转化为以实体肿瘤患者为导向的研究的方法。TACR计划由以下部分组成 79名成员来自15个不同的部门和4个不同的学校和学院。2022年，TACR计划会员每年与癌症相关的直接资助总额为2080万美元，其中750万美元(36%)来自NCI；该计划的同行评审资金总额为1020万美元(49%)。此外，TACR成员拥有1060万美元来自非同行和行业赞助商的赠款。会员共有出版物1457份，其中30.1%为方案内协作占34.8%，方案间协作占34.8%。TACR计划有三个具体的目标：1)开发和应用最先进的分子靶向方法来诊断和治疗癌症； 2)开发和测试新的预测生物标记物和跨肿瘤类型的疾病监测策略；以及3) 从罗杰尔癌症中心的科学计划到有影响力的临床试验的先进概念。